{"id":"W4386270767","doi":"10.1016/s2152-2650(23)01361-7","title":"IBCL-458 Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; Spinal Cord Injury BC; University of British Columbia","funders":"Jewish General Hospital; Royal Adelaide Hospital; McGill University; American Society of Hematology","keywords":"Refractory (planetary science); Follicular lymphoma; Medicine; Safety profile; Follicular phase; Internal medicine; Phases of clinical research; Oncology; Surgery; Lymphoma; Clinical trial; Adverse effect; Materials science","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001309253,0.0005845006,0.001401314,0.0003097358,0.0002265294,0.001053074,0.0004608086,0.0004153336,0.001656389],"category_scores_gemma":[0.0008894616,0.0002533969,0.0009118281,0.0004575874,0.0003321419,0.0006353629,0.0002097457,0.00143114,0.000511547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007905,"about_ca_system_score_gemma":0.0006262252,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008904622,"about_ca_topic_score_gemma":0.004475914,"domain_scores_codex":[0.9996607,0.0001084357,0.00002989937,0.0000543422,0.00006664784,0.00007998077],"domain_scores_gemma":[0.9995315,0.0001148789,0.0001673062,0.00003746105,0.0000490064,0.00009992625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1377766,0.005890649,0.04720831,0.001917735,0.005865669,0.0004916979,0.0003115958,0.002540927,0.06839246,0.0004297341,0.01593923,0.7132354],"study_design_scores_gemma":[0.2597919,0.1797774,0.4204237,0.0007927603,0.01208742,0.004907823,0.0004113281,0.006082503,0.02420821,0.001191992,0.09008312,0.000242064],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9648045,0.02606857,0.0007712603,0.0008990979,0.0001656757,0.0004176869,0.001548017,0.0001594521,0.005165785],"genre_scores_gemma":[0.9863875,0.007116332,0.001126359,0.001221829,0.0001550172,0.0002212824,0.002422563,0.00003458248,0.001314674],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001656389,"threshold_uncertainty_score":0.006924033,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01848741393930723,"score_gpt":0.2924520393836837,"score_spread":0.2739646254443765,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}